CERO - CERo Therapeutics Holdings, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CERO

CERO THERAPEUTICS HOLDINGS, INC.

OTC

$0.01

▲ UP 10.00% (0.00)

KEY STATISTICS

Market Cap$496.24 K

52w High$7.60

52w Low$0.01

Dividend Yield—

Frequency—

P/E—

Volume236.21K

Shares Out.45.11M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Christopher Ehrlich

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 30, 2021

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateDec 2, 2026

DayWednesday

Rev. Est.—

DEC

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-13	Reverse	1:20
2025-01-08	Reverse	1:100

PRICE

$0.01 ▲ UP 10.00% (+$0.00)

OVERLAYS

About CERo Therapeutics Holdings, Inc.

https://www.cero.bio ↗

CERo Therapeutics Holdings, Inc. is an immunotherapy company developing engineered T cell therapies, including CER-1236, for treating hematologic malignancies and solid tumors, based in South San Francisco since 2021.

INDUSTRY

Biotechnology

A PRODUCT CERO THERAPEUTICS HOLDINGS, INC. IS KNOWN FOR

CER-1236

CER-1236, CERo Therapeutics' investigational engineered T-cell therapy in Phase 1, uses phagocytic T-cells to target hematologic cancers like AML, MDS, and myelofibrosis, offering a novel approach beyond traditional CAR-T treatments.